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Zonisamide Efficacy as Adjunctive Therapy
 in Children With Refractory Epilepsy
Abstract
Objective
Approximately one third of epileptic children do not achieve complete 
seizure improvement. Zonisamide is a new antiepileptic drug which is 
effective as adjunctive therapy in treatment of intractable partial seizures. 
The purpose of the current study was to evaluate the effectiveness, safety, 
and tolerability of Zonisamide in epileptic children. 
Materials & Methods
From November 2011 until October 2012, 68 children who referred 
to Children’s Medical Center and Mofid Children Hospital due to 
refractory epilepsy (failure of seizure control with the use of two or 
more anticonvulsant drugs) entered the study. The patients were treated 
with Zonisamide by dose of 2- 12 mg/kg daily in addition to the previous 
medication. We followed the children every three to four-weeks intervals 
based on daily frequency, severity and duration of seizures. During 
the follow-up equal and more than fifty percent reduction in seizure 
frequency or severity known as response to the drug. 
Results
In this study 68 patients were examined that 61 children reached the 
last stage.35 (57.4%) were male and 26 (42.6%) patients were female. 
After first and six months of Zonisamide administration daily seizure 
frequency decreased to 2.95±3.54 and 3.73±3.5 respectively. There 
was significant difference between seizure frequency in first and six 
month after Zonisamide toward initial attacks. After six months ZNS 
therapy a little side effects were created in 10 patients (16.4%) including 
stuttering(4.9%), decreased appetite (4.9%), hallucination (1.6%), 
dizziness(1.6%), blurred vision(1.6%) and suspiring(1.6%) as all of 
them eliminated later dosage reduction.
Conclusion
This study confirms the short term efficacy and safety of Zonisamide in 
children with refractory epilepsies.
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Introduction
About 0.5 to 0.8% of children involved in epilepsy which is the most common cause 
of pediatric neurology clinics referral(1).Approximately eighty thousand new cases of 
epilepsy occur every year in children. Fortunately, many of epileptic children will recover 
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spontaneously and gradually but severe complications 
develop in those with refractory seizure. Several studies 
show that about 10 to 30 percent of people with epilepsy, 
experiencing continuous seizures attacks as intractable 
epilepsy despite adequate anticonvulsant medications. 
Refractory epilepsy characterize lack of seizure control 
regardless of three or four best first-line drugs (as long 
as consumed in adequate dose and duration) (2-4) 
.Zonisamide (1,2 benisoxazol -3- methanesulfonamide) 
is a new generation anticonvulsant With broad spectrum 
antiepileptic activity(5,6).Zonisamide (ZNS) approved 
as monotherapy and add-on therapy of refractory partial 
epilepsies in adults and children. ZNS may be impressive 
in pediatric generalized seizures, particularly for 
myoclonic epilepsies.Furthermore, can be examined as a 
second-choice drug in the treatment of juvenile myoclonic 
epilepsy, infantile spasms and Lennox-Gastaut syndrome 
(LGS).Zonisamide is incomparable to other antiepileptic 
drugs(AEDs) due to chemical structure of non-arylamine 
sulphonamide and multiple modes of antiepileptic 
action(7-9). ZNS mechanisms of action include voltage 
related sodium and T-type calcium channel blockage (main 
pharmacologic effect), decline in glutamate dependent 
synaptic stimulation via potassium evoked responses 
blockade, enhanced gamma-aminobutyric acid 
(GABA) distribution from hippocampus, stabilizing 
neuronal membranes and suppressing neuronal 
hypersynchronization, dopaminergic and serotonergic 
comfort, erythrocyte carbonic anhydrase inhibition and 
destroying nitric oxide and hydroxyl radicals (10-14). 
ZNS represents a favourable pharmacokinetic index as 
absorbed quickly with peak plasma concentrations 2–6 h 
after oral administration and high bioavailability (95%)( 
15). ZNS has a long half-life of about 63 hours and take 
1–2 weeks to get stable state after initiation the profile 
that facilitate once-daily usage (16). Researchers have 
not investigated Zonisamide efficacy in Iranian children 
with various type of seizure in much detail. The aim of 
this study was to evaluate Zonisamide effectiveness in 
children with intractable epilepsy of different seizure 
types and it,s adverse effect characteristics.
Material & Methods
From November 2011 until October 2012, 68 children 
referred to Children’s Medical Center and Mofid 
Children Hospital with refractory epilepsy entered the 
study. Inclusion criteria were children under 14 years 
and refractory epilepsy to previous anti-epileptic drugs 
(more than two conventional and new AEDs). Exclusion 
criteria were children with neurodegenerative diseases or 
hypersensitivity to anticonvulsants. All parents signed a 
written consent for study entry. Careful history containing 
type of seizure, seizure onset, developmental status, 
etiology of seizures, period of the treatment, type of 
antiepileptic drug administration and seizure frequency 
was taken from all patients. Seizures were confirmed and 
quantified by reports of parents, observation of videos that 
were detected by parents and direct observation in Hospital 
before and after treatment. Electroencephalography 
(EEG) was done for all patients. Diffused and continuous 
generalized paroxysmal epileptic discharges considered 
as severely abnormal EEG, when paroxysmal epileptic 
discharges covered more than 50% and 25% of EEG 
recording considered as moderate and mildly abnormal. 
Information from patient’s EEG and magnetic resonance 
imaging (MRI) findings were registered.Then, the 
patients were treated with ZNS by initial dose of 2 
mg/kg daily in two or three divided doses in addition 
to the previous medication (more than two antiepileptic 
drugs / new or conventional/ concurrent AEDs are listed 
in table1). We followed the children every three to 
four-weeks intervals based on daily frequency, severity 
and duration of seizures. According to level of seizure 
response the drug doses were adjusted to maximum 
dose of 12 mg/kg daily.During the follow-up equal and 
more than fifty percent reduction in seizure frequency or 
severity known as response to the drug .Our clinical trial 
study confirmed by ethics Committee of Shahid Beheshti 
University of Medical Sciences. This study was registered 
in Iranian registry of clinical trial (IRCT) with number of 
IRCT2012091210508N2. 
Data Analysis
Data were analyzed using SPSS 15 (SPSS Inc, 
Chicago, Illinios). P-value less than 0.05 was 
considered statistically different.
Results
In this study 68 patients were examined that 61 children 
reached the last stage. Details of patient characteristics 
are listed in Table 1.Of these, 35 (57.4%) were male and 
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and had worsened, respectively(figure.1). Myoclonic 
(54.5%),Infantile spasms (47.1%) and generalized 
tonic clonic (42.9%) were the seizure types with 
the highest response to ZNS in Six-month follow-
up.The type of seizure had significant correlation 
with drug response in this time (p =0.069).None 
of the patients with mixed type of seizure respond 
to ZNS within first or six months review.Based on 
seizure severity and duration reduction there was 
no significant difference in the first month compared 
to six-month follow-up (p= 0.39). After six months 
ZNS therapy a little side effects were created in 10 
patients (16.4%) including stuttering(4.9%), decreased 
appetite(4.9%), hallucination(1.6%), dizziness(1.6%), 
blurred vision(1.6%) and suspiring(1.6%) as all of 
them eliminated later dosage reduction. All of above 
complications observed with ZNS dose more equal 200 
mg/day in patients over 6 years old and weighing more 
than twenty kilograms.
Discussion
This study showed that Zonisamide reduced the daily 
seizure frequency as 38.5% and diminished severity 
and duration of seizure as more than fifty percent in 
40.2% of patients. The findings of the current study 
are consistent with four clinical studies which recently 
performed by Brodie et al, Sackellares et al, Faught 
et al and Schmidt et al who reported responder rates 
up to 28-47% with ZNS (17). Also ZNS effectiveness 
decline the seizure frequency (more than fifty percent )
in 48.7% of patients, reported  by Giangennaro Coppola 
et al. This study confirmed our results(18).Stephen 
LJ has been showed ZNS effect on reducing seizure 
frequency in 39% of users about  more than fifty percent 
Similar to decline rate of 30% reported by Hui Jeen 
Tan et al(19-20). Approximately 31% of patients who 
completed the Claudia B et al study continued to ZNS 
utilization compare to 24% determined by Yuen et al 
for pregabalin(21). In our study, ZNS reduction seizure 
frequency was different in six-month (31.1%) follow-up 
than the one month (49.2%). But the difference was not 
significant (Pvalue > 0.25). This finding is in agreement 
with Hui Jeen Tan et al findings which showed ZNS 
caused seizure diminution of 35.3% in two-month 
follow-up, also seizure had been reduced to 25.5% 
26 (42.6%) patients were female. Age range was from 
1.5 months to 14 years with average of 73.9± 44.04 
months. The age of seizure onset was from 3 days to11 
years, and mean age at seizure onset was 27.1± 28.13 
months. Daily frequency of seizures in patients varied 
from nine attacks every month (0.3 daily) to 50 attacks 
per day with average of 5.43 ± 7.21 seizures per day. The 
most common seizure form was generalized tonic clonic 
in 17 children (27.9%), partial in 16 patients (26.3%) 
(4 simple and 12 complex), and 11 patients (18%) 
with myoclonic seizure (Table 1).According to seizure 
etiology, 26(42.62%) were classified as idiopathic, 
24 (39.34%) as cryptogenic and 11 patients (18%) as 
symptomatic epilepsy. Brain MRI of 19 patients (31.1%) 
were normal while the most common abnormality was 
brain atrophy in 17 children (27.9%)(Table 1). The EEG 
findings were normal, mild, moderate and severely 
abnormal in 4 (6.57%), 18 (29.5%), 24 (39.34% ) and 
15 (24.6%) children respectively (Table1). Patients 
had used minimum 3 and maximum of 15 anti-seizure 
medications, the average number of 7.11± 2.97 prior 
this study. ZNS  used at least 2 to maximum dose of 12 
with mean of  10.4±1.27 mg/kg/day. After first and six 
months of ZNS administration daily seizure frequency 
decreased to 2.95±3.54 and 3.73±3.5 respectively. 
So within three and six months of this drug treatment 
patients daily attacks of seizure reduced up to 45.7% 
and 31.3% in turn. There was significant difference 
between seizure frequency in first (P=0.001) and six 
month (P=0.001) after ZNS toward initial attacks with 
no major discrepancy among three compared to six 
month seizure frequency(P=0.735).On basis of severity 
and duration of seizures in the first month follow-up, 
17 patients (27.9%) had no change, 30 patients (49.2%) 
were responder (reduction of more than fifty percent) 
and 14 patients (22.9%) had reduction less than fifty 
percent(figure.1). The highest response to ZNS was in 
seizure type of infantile spasms (85.7%), generalized 
tonic clonic (58.8%) and myoclonic (54.5%) during  the 
first month review. There was no significant correlation 
between the type of seizure and drug response in this 
time (p = 0.216). In six months follow up seizure 
severity and duration of 25(41%),19 (31.1%),14(23.9%) 
and 3(4.9%) patients did not change, reduced more than 
fifty percent, had reduction lower than fifty percent 
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during twelve-month of follow-up(19). Loscher W et al 
has demonstrated that efficacy of anticonvulsant drugs 
decreased over time due to reduced drug receptor 
sensitivity leading to Pharmacodynamic functional 
tolerance that can even lead to complete loss of drug 
function (22).
ZNS caused seizure deterioration between 9.7% and 
15.7% in study of Giangennaro Coppola et al and Hui 
Jeen Tan et al in turn reported exceed worsening rate of 
4.9% (18-19).
Infantile spasms (66.4%), myoclonic (54.5%) and 
generalized tonic clonic (50.9%)  were the seizure types 
with the highest response to ZNS in our subjects with no 
effect on mixed type seizure. Consistent to the results 
of this study Giangennaro Coppola et al revealed the 
major ZNS efficacy on generalized seizures (57.4%) 
compared to partial types (37.1%)(18).
As well Stephen LJ observed ZNS response on the 
control of generalized seizures (39%) more than the 
partial varieties (12.7%), versus the result reported by 
Hui Jeen Tan et al showed  23.5% in generalized similar 
to 25% for partial seizures (19-20) .Razieh fallah et al 
notified the most effect on myoclonic seizures up to 
62.5%, furthermore contrary to our result showed that 
ZNS was effective in 43% of mixed type epilepsy(14).
Giangennaro Coppola et al observed ZNS complication 
rate of 26.8% (greater  than our report as 16.4%) that 
irritability and drowsiness were the most common 
complication in their study, all complications vanished 
with dose titrative deceleration (18).Hui Jeen Tan et 
al detected visual hallucinations in two patients that 
recovered by reduced the dose of ZNS as we reported (19).
All of our patient’s complications occurred with  high 
dose of ZNS dose (more than 200 mg/day in patients 
over 6 years old and weighting more than twenty 
kilograms). Stephen LJ declared that all 28.6% of his 
patients who have had ZNS complications taking more 
than 200 mg daily, which is similar to our result (20).
So-Hee Eun et al demonstrated that high dose(6-8mg/
kg/day) of ZNS has the same efficacy like low dose(3-
4mg/kg/day) but there was significant difference 
between the two groups in view of associated speech 
complications, this finding support our result about 
language stuttering via ZNS dose more 200mg/day. (23). 
In conclusion, this study confirms the short term 
efficacy and safety of ZNS in children with refractory 
Epilepsies. Future investigations with longer course 
of study are needed to evaluate ZNS prolonged 
effectiveness.
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Table1. Patient Characteristics

















































































































M= month, y= years, MRI=Magnetic resonance imaging, PVL=Periventricular leukomalacia, HVSW= High voltage slow waves
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